INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Faruqi & Faruqi, LLP — a major U.S. securities‑litigation firm — has issued a formal reminder to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE) that the deadline to seek the role of lead plaintiff in a recently filed federal securities class‑action lawsuit is January 16, 2026. According to the firm’s notice, anyone who purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025 and suffered losses may be eligible to participate. The class‑action complaint alleges that Skye and certain executives misled investors about the effectiveness and commercial potential of the company’s drug candidate, nimacimab. Specifically, the suit claims Skye overstated nimacimab’s clinical and regulatory prospects — a claim that crumbled when the company disclosed on October 6, 2025 that the 26‑week Phase 2a study failed to achieve its primary weight‑loss endpoint, and that drug exposure was lower than expected. Following that announcement, Skye’s share price plunged by around 60%, falling $2.85 to close at $1.90 on the same day. Faruqi & Faruqi is urging investors — including potential whistleblowers, former employees, and shareholders — who have information relevant to the company’s conduct to contact the firm directly. #SkyeBioscience #InvestorAlert #SecuritiesFraud #ClassAction #SlimScan #GrowthStocks #CANSLIM